The aims of the present study were to investigate the role of pharmacology in the design of first-in-man (FIM) trials in the Netherlands, and to evaluate the change in design approaches between 2007 and 2015.
Pharmacological vs. classical approaches in the design of first in man clinical drug trials.
CHDR
van den Bogert CA, Cohen AF, Leufkens HGM, van Gerven JMA
